MCL1 and triple-negative breast carcinoma: For instance, the cyclin-dependent kinase inhibitor flavopiridol has been shown to downregulate MCL-1,43 hence conferring increased sensitivity in combination with senolytics in a model of senescent triple-negative breast cancer.44 Interestingly, flavopiridol also inhibited pLGG cells in their proliferation phenotype, probably via CDK inhibition.